These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29468713)

  • 1. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer.
    Diaz-Perez JA; Beveridge MG; Victor TA; Cibull TL
    J Cutan Pathol; 2018 Jun; 45(6):434-438. PubMed ID: 29468713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
    J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
    Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
    Chou S; Hwang SJ; Carlos G; Wakade D; Fernandez-Penas P
    Am J Dermatopathol; 2017 Jan; 39(1):23-27. PubMed ID: 28045749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
    Obara K; Masuzawa M; Amoh Y
    J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
    JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab.
    Feldstein SI; Patel F; Larsen L; Kim E; Hwang S; Fung MA
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e58-e59. PubMed ID: 28776778
    [No Abstract]   [Full Text] [Related]  

  • 10. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
    J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab-induced lichenoid penile ulceration and re-emergent mucocutaneous eruption treated with hydroxychloroquine.
    Headd VA; Mathien A; Pei S; Kuraitis D
    Australas J Dermatol; 2024 Jun; 65(4):e97-e99. PubMed ID: 38337182
    [No Abstract]   [Full Text] [Related]  

  • 13. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
    Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab-induced lichenoid dermatitis occurring in a patient with metastatic melanoma successfully treated with alitretinoin.
    Edwards C; Fearfield L
    Clin Exp Dermatol; 2018 Jul; 43(5):609-610. PubMed ID: 29453770
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
    Schaberg KB; Novoa RA; Wakelee HA; Kim J; Cheung C; Srinivas S; Kwong BY
    J Cutan Pathol; 2016 Apr; 43(4):339-46. PubMed ID: 26762844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
    Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
    Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
    [No Abstract]   [Full Text] [Related]  

  • 17. Postherpetic Granulomatous Dermatitis in a Man Treated With Nivolumab.
    Martín-Carrasco P; Pérez-Ruiz C; de Zulueta-Dorado T; Conejo-Mir J
    Actas Dermosifiliogr; 2017 Oct; 108(8):783-784. PubMed ID: 28532783
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
    Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
    J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral and mucosal lichenoid drug eruption under anti-PD-1].
    Amini-Adle M; Balme B; Locatelli-Sanchez M; Souquet PJ; Dalle S
    Ann Dermatol Venereol; 2018 Nov; 145(11):725-727. PubMed ID: 30126642
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.